Intelligene Biosystems Files IPO Prospectus: Pioneering Next-Generation Mass Spectrometry Platform for High-Precision Quantitative Analysis Across Full Mass Range
From the “Zhu Liangyi Analytical Instrument Innovation Award” to the “CISILE 2019 Gold Award for Independent Innovation,” and further to the “BCEIA Gold Award,” Intelligene Biosystems has garnered multiple prestigious accolades within China’s scientific instrument sector in just over a year. What sets this award-winning company, which has secured over RMB 100 million in financing, apart? The answer lies in the team and technology behind Intelligene Biosystems.
Intelligene Biosystems was founded in Qingdao in 2013, co-established by Dr. Zhou Xiaoguang and Dr. Li Yuntao. The company specializes in the research and development, manufacturing, and sales of life science analytical instruments, consumables, and solutions. It has established sub-centers for R&D, production, application development, sales, and services in Boston (USA), Beijing, Qingdao, Nanjing, and Hangzhou.
Dr. Zhou Xiaoguang, Co-founder of the Company, is a senior mass spectrometry expert who previously worked at Thermo Fisher and ABI. With nearly 30 years of experience in R&D and R&D management of mass spectrometry instruments, he has participated in or managed the development of various commercial mass spectrometers, including triple quadrupole, ion trap, and time-of-flight mass spectrometers. Most of the products he developed were among the world’s first commercially available mass spectrometers. Dr. Li Yuntao, another Co-founder of Intelligene Biosystems, is an Associate Research Fellow at the Institute of Semiconductors, Chinese Academy of Sciences. His primary research interests focus on biosensors and life science detection instruments. He possesses over ten years of experience in the R&D, sales, and management of life science instruments.
Beyond Dr. Zhou Xiaoguang and Dr. Li Yuntao, Intelligene Biosystems is backed by a top-tier technical team and an experienced operations and management team. The R&D team is led by 20 senior engineers, with more than 50% of its members holding master’s or doctoral degrees. The operations team is headed by executives from leading domestic and international medical device companies, each boasting over ten years of industry experience.
Naturally, the products developed by such a robust team are not to be underestimated. VCBeat conducted an in-depth interview with Dr. Li Yuntao, co-founder of Intelligene Biosystems, to gain insights into the company’s two core technological platforms: the “New-Generation Broad-Spectrum Quantitative Time-of-Flight Mass Spectrometry Platform (QuanTOF)” and the “Microfluidic Nucleic Acid Quantitative Analysis Platform (QuanPLEX).”
QuanTOF is the next-generation matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) platform under Intelligene Biosystems.
“In the MALDI-TOF MS instrument market, there are two major core pain points,” Dr. Li Yuntao introduced to VCBeat. “First, traditional mass spectrometry detection suffers from low reproducibility (below 70%), which limits it to qualitative analysis and makes quantitative analysis a significant challenge. Second, the ‘mass focusing’ limitation of time-of-flight mass spectrometers restricts the range for high-resolution and high-sensitivity analysis to 8,000–10,000 Daltons, thereby severely constraining the application of MALDI-TOF MS in traceability analysis.”
Due to these limitations, MALDI-TOF MS is currently primarily focused on two qualitative analytical applications in the clinical field: microbial identification and nucleic acid typing analysis. Although its range of applications remains narrow, its installation base in clinical settings far exceeds that of other mass spectrometers, owing to advantages such as ease of use, high detection efficiency, and low testing costs.
In the IVD sector, the qualitative analysis market, which includes applications such as microbial identification and nucleic acid analysis, accounts for approximately 5% of the total IVD market share, representing a value of around $2 billion. The core of the IVD industry lies in the quantitative analysis of proteins and metabolites, which constitutes roughly 70% of the entire IVD market, with a market size of approximately $50 billion.
“Targeting a $50 billion market and endowing time-of-flight mass spectrometry with the capability for clinical quantitative analysis is the reason we developed QuanTOF,” said Dr. Li Yuntao. “We have redesigned the time-of-flight mass spectrometer from first principles, updating various performance components and key technologies, including optical path design, ion extraction methods, ion transmission pathways, and ion detection to data acquisition. This redesign enables QuanTOF to achieve a quantitative reproducibility accuracy of over 95%, meeting the precision requirements for clinical quantification. It also renders the ‘focus on mass resolution’ of MALDI-TOF MS less critical, significantly enhancing the instrument’s scalability in traceability applications, such as microbial identification, allowing for the differentiation of bacterial genera with closely related genotypes.”
Furthermore, as a “next-generation” MALDI-TOF MS system, it has achieved qualitative improvements in multiple performance metrics, with a significant enhancement being the efficiency of mass spectrometry imaging.
As the latest application technology in the field of mass spectrometry, mass spectrometry imaging (MSI) is considered to have extensive application value in clinical pathological analysis, representing a disruptive upgrade and replacement for existing immunohistochemistry techniques. However, conventional MSI technologies fall far short of meeting the requirements for imaging speed in clinical pathological analysis.
“Taking a 1 cm² tissue section scanned at a spatial resolution of 10 micrometers as an example, even the most advanced international systems require more than 6–8 hours, rendering them impractical for clinical applications. Last year, we announced that we had improved the world record for MALDI-TOF MS imaging by tenfold,” said Dr. Li Yuntao. “A standard clinical pathology slide can now be imaged in under 30 minutes. This performance enhancement has enabled MALDI-TOF MS imaging technology to truly acquire the capability for clinical pathological analysis.”
Currently, based on the QuanTOF platform, Intelligene Biosystems has developed clinical solutions including the QuanIMAGE Imaging Mass Spectrometry System, the QuanSNP Nucleic Acid Genotyping System, the QuanID Microbial Identification System, the QuanTOF Biomarker Analysis System, and the QuanGHb Glycated Hemoglobin Quantitative Analysis System.
QuanTOF is a cutting-edge mass spectrometer, well-suited for deployment in central laboratories; another core product under Intelligene Biosystems, QuanPLEX, targets grassroots-level applications.
QuanPLEX is a microfluidic genetic testing platform based on quantitative fluorescence PCR technology. A major pain point of traditional genetic testing is its stringent requirements for the testing environment, which necessitates substantial investment in building dedicated molecular biology laboratories. Consequently, it is currently difficult to achieve on-site, rapid analysis in genetic testing, making point-of-care testing (POCT) unfeasible.
“Given the inherent characteristics of genetic testing, microfluidics is currently known to be a relatively suitable application tool,” said Dr. Li Yuntao. “In essence, microfluidics is a front-end sample processing technology that integrates manual procedures originally performed in laboratories onto a chip. Through designs such as reagent immobilization on the chip, issues like aerosol contamination are avoided. As a result, QuanPLEX, which leverages microfluidic technology, can be deployed in field settings or on physicians’ desks.”
By integrating microfluidic chips, QuanPLEX enables parallel detection of 32 analytes from a single sample and offers customized chips in various specifications to meet customers’ specific testing requirements. As reactions occur within the chip, the reaction volume is significantly reduced, allowing for more precise temperature control compared to conventional PCR. Consequently, QuanPLEX achieves a detection speed that is more than twice as fast as traditional PCR.
Currently, three diagnostic applications have been developed based on the QuanPLEX platform: the QuanPLEX Rapid Identification System for Foodborne Pathogens, the QuanPLEX Avian Influenza Virus Detection System, and the QuanPLEX Respiratory Pathogen Detection System.
Dr. Li Yuntao emphasized that neither QuanTOF nor QuanPLEX is merely a scientific instrument or a specific application; rather, they represent core technology platforms within the in vitro diagnostics (IVD) industry chain. Based on these platforms, various clinical applications encompassing the three major omics of life sciences—genomics, proteomics, and metabolomics—can be developed. These applications, particularly those developed on the QuanTOF platform, will constitute a revolutionary upgrade over existing detection technologies. Therefore, through the joint efforts of Intelligene Biosystems and its upstream and downstream partners, it is expected to establish a vast clinical ecosystem based on time-of-flight mass spectrometry, which will not only propel the success of Intelligene Biosystems but also benefit a cohort of its partners.
“Entrepreneurship is a process of continuously solving one problem after another while moving forward,” stated Dr. Li Yuntao, the founder. “For our future development, we seek like-minded partners to advance together and achieve win-win cooperation. From a strategic investment perspective, we require investors who can provide industrial resources; therefore, we are highly selective in choosing our investors.”
It is reported that Intelligene Biosystems will soon launch a new round of financing, with an initial estimated amount exceeding RMB 100 million. The proceeds will be used for new product research and development and market channel construction. Interested parties are requested to contact Xiao Yun, the financing assistant at VCBeat:DongMai_Investent。